NEUROMYELITIS OPTICS THERAPY MARKET ANALYSIS(2020-2027)

1

• Coherent Market Insights
• Market Research and Business Consulting Services
• https//www.coherentmarketinsights.com/
• COVID-19 Impact Tracker

2
NEUROMYELITIS OPTICS THERAPY MARKET ANALYSIS
(2020-2027)

• Neuromyelitis Optics Therapy Market, by Drug
  Class (Corticosteroids, Immunosuppressive Agents
  (Azathioprine, Mycophenolate Mofetil, Rituximab,
  Eculizumab), and Others), by Distribution Channel
  (Online Retail Pharmacies and Offline Retail
  Pharmacies), and by Region (North America, Latin
  America, Europe, Middle East, Asia Pacific, and
  Africa)

3

• Neuromyelitis optica is an autoimmune disorder,
  in which white blood cells and antibodies attack
  optic nerve as well as spinal cord. Furthermore,
  damage of the optics nerves results in pain and
  loss of vision, while damage of spinal cord
  results in paralysis of legs or arms, loss of
  sensation in legs and arms, and problem in the
  function of bladder bowel.
• Moreover, there is no cure for neuromyelitis
  optica disorder, but there are therapies to treat
  acute attack of relapses, and to reduce symptoms.
  Neuromyelitis optica attacks and Neuromyelitis
  optica relapses are often treated with plasma
  exchange and corticosteroids. Moreover, initial
  symptoms of neuromyelitis optica such as vision
  loss and paralysis can be improve with high doses
  of intravenous corticosteroids. On the other
  hand, plasma exchange can be used as alternative,
  if the patient do not respond to intravenous
  corticosteroids. For long term suppression of
  disease, immunosuppressive agents such as
  azathioprine, mycophenolate mofetil, and
  rituximab are used to prevent the attack.
  Sometimes, azathioprine and mycophenolate mofetil
  are used with the low doses of corticosteroid to
  prevent the attack.

4
Global Neuromyelitis Optica Therapy Market
Drivers

• The global neuromyelitis optica therapy market is
  expected to witness significant growth over the
  forecast period, owing to increasing
  collaborations to launch new drugs for the
  treatment of neuromyelitis optica spectrum
  disorder. For instance, in May 2019, in China,
  Viela Bio, Inc. entered into strategic
  collaboration with Hansoh Pharmaceutical Group
  Company Limited (Hansoh Pharma) to develop as
  well as commercialize inebilizumab drug for the
  treatment of autoimmune disorder such as
  neuromyelitis optica spectrum disorder. From the
  same source, in May 2019, Viela Bio had presented
  positive result from the pivotal study of
  inebilizumab in patient. Moreover, currently
  inebilizumab drug is not approved by the U.S Food
  and Drug Administartion (FDA) for sale in China
  and U.S

5

• Furthermore, rising incidence of neuromyelitis
  optica disorder among people is expected to
  propel global neuromyelitis optica therapy market
  growth. For instance, according to the U.S
  National Library of Medicine (NHS) 2019 report,
  prevalence of neuromyelitis optica spectrum
  disorders (NMOSD) is commonly observed in nations
  with a predominately non-Caucasian population and
  estimated to be high as 10 per 100,000
  individuals.

6

• Global Neuromyelitis Optica Therapy Market
  Restraints
• However, high cost of drug such as eculizumab for
  the treatment of neuromyelitis optica spectrum
  disorder (NMOSD) yet remains one of the major
  restraints for global neuromyelitis Optica
  therapy market growth. For instance, cost of
  eculizumab is US 500,000 per patient per year,
  which is one of the most expensive therapies in
  the world for the treatment of neuromyelitis
  optica spectrum disorder (NMOSD).
• Moreover, side effects associated with the
  eculizumab such as upper respiratory tract
  infection, back pain, anemia, nasal congestion,
  urinary tract infection for the treatment of
  neuromyelitis optica spectrum disorder (NMOSD) is
  another factor that is expected to hamper the
  global neuromyelitis optica therapy market
  growth.

7

• Global Neuromyelitis Optica Therapy Market
  Regional Analysis
• .Among regions, North America is expected to
  account for highest market share in the global
  neuromyelitis optica therapy market, owing to
  factors such as increasing approval of drugs for
  the treatment of neuromyelitis optica spectrum
  disorder (NMOSD) by company. For instance, in
  January 2019, Alexion Pharmaceuticals, Inc.
  received approval by the U.S Food and Drug
  Administartion (FDA) for eculizumab
  (Soliris) drug for the treatment of neuromyelitis
  optica spectrum disorder (NMOSD) in adult
  patients.  Furthermore, from the same source,
  eculizumab (soliris) has reduced the need of
  corticosteroid and plasma exchange to prevent
  acute attack in patients, who are suffering from
  neuromyelitis optica spectrum disorder (NMOSD).

8

• Asia Pacific is expected to exhibit highest CAGR
  in the global neuromyelitis optica therapy market
  in the forecast period due to increasing approval
  of drug for the treatment of neuromyelitis optica
  spectrum disorder (NMOSD) by company. For
  instance, in November 2019, Alexion
  Pharmaceuticals, Inc. received approval from
  Japans Ministry of Health, Labour and Welfare
  (MHLW) for its Soliris (eculizumab) drug for the
  treatment of neuromyelitis optica spectrum
  disorder (NMOSD) to prevent relapse in patient.  

9

• Furthermore, increasing number of clinical trials
  of drug for the treatment of neuromyelitis optica
  spectrum disorder (NMOSD) by company is another
  factor that is expected to drive the global
  neuromyelitis optica therapy market growth. For
  instance, in September 2019, Chugai
  Pharmaceutical Co., Ltd.  announced positive
  results of its phase 3 clinical study of
  satralizumab drug, for the treatment of
  neuromyelitis optica spectrum disorder (NMOSD).
  From the same source, in 2019, Satralizumab had
  shown safety profile during the clinical trial
  and is first investigational drug that had
  demonstrated benefits both as a monotherapy and
  add-on therapy to baseline treatment in two
  different clinical trials. Furthermore, from the
  same source, in 2019, Chugai Pharmaceutical Co.,
  Ltd also announced that they are going to
  collaborate with F. Hoffmann-La Roche AG Company.
  The main objective of this collaboration with
  Hoffmann-La Roche AG company is to file global
  regulatory application and bring Satralizumab as
  a potential new treatment to patients as soon as
  possible.

10

• Furthermore, in October 2019, European Medicines
  Agency (EMA) and U.S. FDA accepted the marketing
  authorization of Satralizumab drug for the
  treatment of neuromyelitis optica spectrum
  disorder in adults and adolescent patients, which
  was announced by Chugai Pharmaceutical Co., Ltd.

11

• Global Neuromyelitis Optica Therapy Market Key
  Players
• Key players operating in the global neuromyelitis
  optica therapy market include Alexion
  Pharmaceuticals Inc., Chugai Pharmaceutical Co.,
  Ltd., Viela Bio, Inc, Hansoh Pharmaceutical Group
  Company Limited, AstraZeneca plc, F. Hoffmann-La
  Roche AG, Zydus Pharmaceuticals (USA) Inc., Alkem
  Laboratories, Hikma Pharmaceuticals USA Inc., and
  Sandoz Inc.

12

• Market Taxonomy
• On the basis of drug class, the global
  neuromyelitis optica therapy market is segmented
  into
• Corticosteroids
• Immunosuppressive Agents 
• Azathioprine
• Mycophenolate Mofetil
• Rituximab
• Eculizumab
• Others

13

• On the basis of distribution channel, the global
  neuromyelitis optica therapy market is segmented
  into
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• On the basis of region, the global neuromyelitis
  optica therapy s market is segmented into
• North America
• Latin America
• Europe
• Middle East
• Asia Pacific
• Africa

14

• Request Sample Report
• Request Customization
• Download PDF Brochure
• Talk to Analyst
• Buy Now
• Referencehttps//www.coherentmarketinsights.com/o
  ngoing-insight/neuromyelitis-optics-therapy-market
  -4148

15
About Us

• Coherent Market Insights is a global market
  intelligence and consulting organization focused
  on assisting our plethora of clients achieve
  transformational growth by helping them make
  critical business decisions.
• What we provide
• Customized Market Research Services
• Industry Analysis Services
• Business Consulting Services
• Market Intelligence Services
• Long term Engagement Model
• Country Specific Analysis

16
Contact Us

• Mr. Shah
• Coherent Market Insights Pvt.Ltd.
• Address 1001 4th Ave, 3200 Seattle, WA 98154,
  U.S.
• Phone [phone]
• Email sales_at_coherentmarketinsights.com

17

• Thank You!
• Kindly follow CMI Social Media
  Profiles for the latest company updates
• Facebook
• Linkedin
• Twitter
• https//www.coherentmarketinsights.com/